Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00044759 |
To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
Condition | Intervention | Phase |
---|---|---|
Hematologic Neoplasms |
Drug: Piperacillin/Tazobactam (Tazocin) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Medical Monitor, MD | Wyeth |
Study ID Numbers: | 0910B1-308 |
Study First Received: | September 4, 2002 |
Last Updated: | October 8, 2007 |
ClinicalTrials.gov Identifier: | NCT00044759 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hematologic Neoplasms |
Fever Anti-Bacterial Agents Penicillanic Acid Cefepime Hematologic Neoplasms |
Hematologic Diseases Tazobactam Piperacillin Piperacillin-tazobactam combination product Lymphoma |
Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Hematologic Neoplasms Hematologic Diseases Tazobactam Enzyme Inhibitors Piperacillin-tazobactam combination product |
Pharmacologic Actions Anti-Bacterial Agents Neoplasms Neoplasms by Site Penicillanic Acid Therapeutic Uses Piperacillin |